Demant ASWILYY 94 Return-on-Tangible-Asset is 4.75% as of Dec. 2025, which is 65% below its 10-year median of 13.49. GuruFocus rates WILYY with a GF Score™ of 94/100 and a GF Value™ of $23.78 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Demant AS ranks better than 78.76% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Demant AS's annualizedNet Income for the quarter that ended in Dec. 2025 was $134 Mil. Demant AS's average total tangible assets for the quarter that ended in Dec. 2025 was $2,823 Mil. Therefore, Demant AS's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 4.75%.
The historical rank and industry rank for Demant AS's Return-on-Tangible-Asset or its related term are showing as below:
WILYY'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 8.56 Med: 13.49 Max: 19.37
Current: 8.64
During the past 13 years, Demant AS's highest Return-on-Tangible-Asset was 19.37%. The lowest was 8.56%. And the median was 13.49%.
WILYY's Return-on-Tangible-Asset is ranked better than 78.76% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.57
vs WILYY: 8.64
Demant AS (OTCPK:WILYY) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Demant AS Return-on-Tangible-Asset Related Terms
Demant AS Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Demant AS's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WILYY vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Demant AS's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Demant AS Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Demant AS's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Demant AS's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 4.75% mean?
Demant AS (WILYY) has a Return-on-Tangible-Asset of 4.75% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Demant AS and its competitors. This is 65% below median its historical median of 13.49. Over the past decade, Demant AS's Return-on-Tangible-Asset has ranged from 8.56 to 19.37. According to the industry distribution chart, Demant AS ranks #182 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 21.2%.
Is Demant AS's Return-on-Tangible-Asset too high?
Demant AS's current Return-on-Tangible-Asset of 4.75% is 65% below median its 10-year median of 13.49. Over the past 10 years, this metric has ranged from a low of 8.56 to a high of 19.37. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.57. Demant AS's value of 4.75% is 733.3% above this industry median. Based on the distribution chart, Demant AS ranks #182 out of 857 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Demant AS has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Demant AS's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Demant AS ranks #182 out of 857 companies for Return-on-Tangible-Asset. This places Demant AS in the top 21% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.57. Demant AS's value of 4.75% is 733.3% above this benchmark. Historically, Demant AS's own Return-on-Tangible-Asset has ranged from 8.56 to 19.37 over the past decade. While the company's 10-year median is 13.49 vs. the industry median of 0.57, Demant AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.57, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Demant AS's current Return-on-Tangible-Asset of 4.75% is 733.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Demant AS and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Demant AS's current Return-on-Tangible-Asset is 4.75%, which is 65% below median its own 10-year median of 13.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Demant AS stock overvalued right now?
Based on GuruFocus' analysis, Demant AS (WILYY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.78, compared to a current price of $20.66 — trading 13.1% below its estimated fair value. The current Return-on-Tangible-Asset is 4.75%, which is 65% below median its 10-year median of 13.49 and 733.3% above the Medical Devices & Instruments industry median of 0.57. Demant AS's overall GF Score™ is 94/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Demant AS (WILYY), the current Return-on-Tangible-Asset is 4.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Demant AS (WILYY) Overvalued in 2026?
Based on GuruFocus' analysis, Demant AS stock appears to be undervalued.
The current stock price of $20.66 is trading 13.1% below its estimated GF Value™ of $23.78.
GuruFocus considers Demant AS to be Modestly Undervalued.
Key valuation signals for WILYY:
Return-on-Tangible-Asset: 4.75% (65% below median its 10-year median of 13.49)
GF Value™: $23.78 vs. price of $20.66 (13.1% below fair value)
Industry Position: 733.3% above the Medical Devices & Instruments median (#182 of 857)
No single metric tells the full story. See the WILYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and diagnostic equipment. More than 80% of the company's sales come from North America and Europe.
94GF Score
Get the complete analysis for WILYY
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WILYY has been successfully added to your 
